Retatrutide vs Tirzepatide: What's the Key Difference?
Tirzepatide and retatrutide are next‑generation metabolic therapies. Tirzepatide targets two pathways (GLP‑1 + GIP). Retatrutide activates three (GLP‑1 + GIP + glucagon receptor).
Adding glucagon changes the physiology: it can increase energy expenditure and lipolysis, potentially enhancing weight loss and metabolic outcomes. That added pathway also requires careful balancing because glucagon affects glucose regulation—early trials are promising but demand close monitoring and dose optimization.
